AR087508A1 - 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol - Google Patents

3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol

Info

Publication number
AR087508A1
AR087508A1 ARP120102929A ARP120102929A AR087508A1 AR 087508 A1 AR087508 A1 AR 087508A1 AR P120102929 A ARP120102929 A AR P120102929A AR P120102929 A ARP120102929 A AR P120102929A AR 087508 A1 AR087508 A1 AR 087508A1
Authority
AR
Argentina
Prior art keywords
benzyl
alkyl
halo
heteroaryl
hydrogen
Prior art date
Application number
ARP120102929A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of AR087508A1 publication Critical patent/AR087508A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP120102929A 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol AR087508A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177119 2011-08-10

Publications (1)

Publication Number Publication Date
AR087508A1 true AR087508A1 (es) 2014-03-26

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102929A AR087508A1 (es) 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol

Country Status (24)

Country Link
US (7) US8906923B2 (enExample)
EP (1) EP2742045B1 (enExample)
JP (2) JP5921687B2 (enExample)
KR (1) KR101996862B1 (enExample)
CN (2) CN103874698B (enExample)
AR (1) AR087508A1 (enExample)
AU (1) AU2012293621B2 (enExample)
BR (1) BR112014003063B1 (enExample)
CA (1) CA2842518C (enExample)
CL (1) CL2014000289A1 (enExample)
DK (1) DK2742045T3 (enExample)
EA (1) EA201490438A1 (enExample)
ES (1) ES2721658T3 (enExample)
HU (1) HUE042978T2 (enExample)
IL (1) IL230549A (enExample)
JO (1) JO3611B1 (enExample)
MX (1) MX348128B (enExample)
PE (1) PE20141410A1 (enExample)
PH (1) PH12014500317A1 (enExample)
TR (1) TR201905537T4 (enExample)
TW (1) TWI568731B (enExample)
UA (1) UA111210C2 (enExample)
UY (1) UY34253A (enExample)
WO (1) WO2013021054A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6294822B2 (ja) 2011-08-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー 抗菌性ピペリジニル置換3,4−ジヒドロ−1h−[1,8]−ナフチリジノン類
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
CN104981466B (zh) * 2012-08-10 2019-06-14 爱尔兰詹森科学公司 抗细菌化合物
US9540324B2 (en) 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
PL3880675T3 (pl) * 2018-11-12 2025-02-10 Debiopharm International Sa Związki antybiotykowe, sposoby ich wytwarzania, kompozycje farmaceutyczne zawierające te związki oraz ich zastosowanie
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
AU2022236404A1 (en) * 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
EP1225895B1 (en) 1999-10-08 2005-05-04 Affinium Pharmaceuticals, Inc. Fab i inhibitors
ATE332130T1 (de) 1999-10-08 2006-07-15 Affinium Pharm Inc Fab-i-hemmer
NZ517706A (en) 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
SI1828167T1 (sl) 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2687533B1 (en) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
WO2011061214A1 (en) 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Hivの治療のための組成物および方法
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
US9394295B2 (en) 2011-08-10 2016-07-19 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
JP6294822B2 (ja) 2011-08-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー 抗菌性ピペリジニル置換3,4−ジヒドロ−1h−[1,8]−ナフチリジノン類

Also Published As

Publication number Publication date
PH12014500317A1 (en) 2014-04-14
US10501463B2 (en) 2019-12-10
JO3611B1 (ar) 2020-08-27
MX348128B (es) 2017-05-26
US20150080413A1 (en) 2015-03-19
US20180105525A1 (en) 2018-04-19
TR201905537T4 (tr) 2019-05-21
CN105461684A (zh) 2016-04-06
EP2742045B1 (en) 2019-01-23
KR20140072034A (ko) 2014-06-12
HK1199243A1 (zh) 2015-06-26
JP2014531404A (ja) 2014-11-27
IL230549A0 (en) 2014-03-31
BR112014003063A2 (pt) 2017-02-21
US9290493B2 (en) 2016-03-22
JP2016190843A (ja) 2016-11-10
AU2012293621B2 (en) 2016-07-21
WO2013021054A1 (en) 2013-02-14
US20170174683A1 (en) 2017-06-22
US20190084982A1 (en) 2019-03-21
UA111210C2 (uk) 2016-04-11
TWI568731B (zh) 2017-02-01
PE20141410A1 (es) 2014-10-13
NZ620212A (en) 2015-10-30
MX2014001600A (es) 2014-04-25
EP2742045A1 (en) 2014-06-18
CA2842518C (en) 2019-07-23
CA2842518A1 (en) 2013-02-14
US8906923B2 (en) 2014-12-09
HK1223352A1 (zh) 2017-07-28
US9617262B2 (en) 2017-04-11
KR101996862B1 (ko) 2019-07-05
TW201313714A (zh) 2013-04-01
US20140171451A1 (en) 2014-06-19
AU2012293621A1 (en) 2014-02-13
HUE042978T2 (hu) 2019-07-29
BR112014003063B1 (pt) 2020-11-17
CN105461684B (zh) 2018-09-25
ES2721658T3 (es) 2019-08-02
JP5921687B2 (ja) 2016-05-24
CN103874698A (zh) 2014-06-18
CL2014000289A1 (es) 2014-07-11
UY34253A (es) 2013-02-28
DK2742045T3 (en) 2019-04-23
US10526331B2 (en) 2020-01-07
US20190194194A1 (en) 2019-06-27
US10155759B2 (en) 2018-12-18
CN103874698B (zh) 2016-03-23
EA201490438A1 (ru) 2014-06-30
US9884864B2 (en) 2018-02-06
IL230549A (en) 2017-07-31
US20160194324A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
AR087508A1 (es) 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PH12015501083B1 (en) Novel pyridine derivatives
MY153617A (en) Pyridin-4-yl derivatives
AR092790A1 (es) Derivados bencimidazolicos del acido hidroxamico
AR073598A1 (es) Pirrolidinas 2-carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas como agentes anticancer.
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
PE20170939A1 (es) Pirimidinonas como inhibidores del factor xia
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR082638A1 (es) Derivados de tetrahidropiran utiles como pesticidas
PH12015501843A1 (en) Novel pyrazol derivatives
PH12015501073A1 (en) Novel pyridine derivatives
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
SG195118A1 (en) Process for the production of estetrol intermediates
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
AR066153A1 (es) Derivados de piperidina / piperazina
MY169179A (en) Novel piperidine compound or salt thereof
PH12015501933B1 (en) Novel pyridine derivatives
MX2015006930A (es) Compuestos de isoxazol amina sustituidos como inhibidores de scd1.
AR096152A1 (es) Derivados de purina
PH12016500152A1 (en) Novel triazine derivative

Legal Events

Date Code Title Description
FG Grant, registration